Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.

@article{Yum2010ComparativeIV,
  title={Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.},
  author={Jong Hwa Yum and Sung Hak Choi and Dongeun Yong and Yunsop Chong and Weon Bin Im and Dong-Kwon Rhee and Kyungwon Lee},
  journal={Antimicrobial agents and chemotherapy},
  year={2010},
  volume={54 12},
  pages={
          5381-6
        }
}
Resistance of Gram-positive pathogens to first-line antimicrobial agents has been increasing in many parts of the world. We compared the in vitro activities of torezolid with those of other antimicrobial agents, including linezolid, against clinical isolates of major aerobic and anaerobic bacteria. Torezolid had an MIC(90) of ≤0.5 μg/ml for the Gram-positive bacterial isolates tested and was more potent than either linezolid or vancomycin. 

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Tedizolid for the management of human infections: in vitro characteristics.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2014
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Tedizolid inhibits MUC5AC production induced by methicillin-resistant Staphylococcus aureus in human airway epithelial cells.

  • Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Mechanism of action of the oxazolidinone antibacterial agents.

  • Expert opinion on investigational drugs
  • 1999
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Efficacy of TR - 701 in a phase 2 randomized , double - blind study in patients with severe complicated skin and skin structure infections ( cSSSI ) , abstr

M. T. Sweeney, G. E. Zurenko
  • 2009

Efficacy of TR-701 in a phase 2 randomized, double-blind study in patients with severe complicated skin and skin structure infections (cSSSI), abstr. L1-335

J. Surber, P. Mehra, +8 authors P. Prokocimer
  • Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.,
  • 2009
VIEW 1 EXCERPT

The new oxazolidinone, TR-700 (DA7157): effects of pH, inoculum, serum, and media on antibacterial activity, abstr. F1-1690

S. Choi, W. Im, J. Rhee
  • Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.,
  • 2007
VIEW 1 EXCERPT

High prevalence of cefazidime - resistant Klebsiella pneumoniae and increase of imipenem - resistant Pseudomonas aeruginosa and Acinetobacter spp . in Korea : a KONSAR program in 2004

J. K. Rhee
  • Yonsei Med . J .
  • 2006